Nevertheless, despite the reduced glycosuric effects of SGLT-2 inhibition in people with T2DM and CKD, lower eGFR has not been shown to attenuate these weight-lowering effects, at least within the range of eGFR studied to date. This evidence concerns the gene SLC5A2 and chronic kidney disease.